Full Signal Podcast: "Bullish stocks NO ONE talks about!" with Lou Basenese
Host: Phil Rosen | Guest: Lou Basenese
Release Date: March 3, 2026

Episode Overview

In this episode, host Phil Rosen sits down with veteran market strategist and founder of The Big Skinny, Lou Basenese, for a high-impact conversation about overlooked bullish opportunities in today’s markets. The pair dig into the misunderstood AI trade, sector rotations, emerging biotech innovation, the rebound in small caps, and specific stock ideas. Throughout, Lou shares his contrarian insights, fundamental strategies, and his best actionable takes—backed by data, history, and sector experience.

Key Themes and Discussion Points

1. The AI Trade: Disruption, Confusion, and Opportunity

[00:00–06:08]

• Market Perception vs. Reality:
  • Lou argues the current narrative around AI is confused; the same pundits call AI a "bubble" while declaring it is "destroying" entire industries.

    "It can't be both. It's not a bubble and it's destroying—or somewhere in the middle where we don't know the exact impact... that's why the market is so confused." — Lou [00:42]

• Nvidia vs. Walmart: Earnings Sanity Check:
  • Lou points out Nvidia trading at a lower forward earnings multiple than Walmart, despite Nvidia’s higher growth—a clear market dislocation. He leans toward following earnings, favoring Nvidia at current levels (~$176–$177).
• Software Sector Sell-Off:
  • Skepticism abounds that AI will replace traditional software, but Lou argues entrenched players (e.g., Microsoft) will adapt and that employment in software development hasn’t dropped.

    "If AI is truly disrupting software, then the job postings for software developers... should be going down... they've actually been pretty steady." — Lou [03:23]

  • He suggests firms are using AI as an accelerant, not a replacement.
• AI as Accelerated Innovation:
  • Lou’s definition: “AI should stand for accelerated innovation.” He shares anecdotes of serial entrepreneurs using AI tools to launch and scale more projects faster than ever.

    "[They] feel like there's this window... 6 to 18 months to really maximize your productivity before AI changes the world." — Lou [05:30]

2. Tech Layoffs: Scapegoating AI vs. Right-Sizing

[06:08–08:30]

• Block and Big Tech Layoffs:
  • Lou sees recent layoffs (e.g., Block’s 40% cut) as a return to operational efficiency, not AI-driven job loss.

    "You're going to see that... they point to or allude to AI when it's really just right sizing." — Lou [07:16]

  • Commentary on Silicon Valley’s over-hiring habits and investors' positive market response when companies streamline.

    "Your revenue per employee now just shot through the roof... Wall Street valuations... that's a rational response." — Lou [08:00]

3. Biotech: Innovation, M&A, and the Best Risk-Reward

[09:37–14:54]

• Big Pharma’s Patent Cliff:
  • $100–$180 billion in revenue needs replacement as drugs go off-patent by 2027–28; pharma will acquire, not make, new hits fast enough.

    "There's only one natural solution. You have to acquire it to replenish pipelines." — Lou [09:54]

• Biotech ETF Play:
  • XBI ETF (small/mid-cap focus) is Lou’s top way to get diversified exposure, given biotech’s volatility and binary risks (bad data or cash flow shortages).
  • He breaks down biotech’s development phases and stresses the sector’s dependence on good clinical data.

    "Two things ruin biotechs: they run out of cash or the data is not good enough..." — Lou [12:28]

• Regulatory/Macro Risks & AI Tailwinds:
  • Regulatory change is an ever-present risk but not structural enough to turn Lou bearish due to unmet medical needs.
  • AI is an accelerant—the drug discovery timeline may shrink, and precision improve, but full valuation impact is still pending.

    "AI is like... an accelerant. It hopefully can compress that drug development timeline... increase the efficacy." — Lou [13:53]

4. Energy: From Pariah to Star Sector

[14:54–17:05]

• 2025–26’s Contrarian Rebound:
  • Energy went from most underweighted (3% of S&P 500, 14.5x earnings) to leading sector performance with a 22% jump YTD.
  • Supply-demand issues still favor continued strength; lower prices curtail production, setting up future deficits.
• How to Play Energy:
  • Lou’s personal bias from industry experience aside, he recommends XLE ETF for diversified exposure.
  • Chevron benefits most from Venezuela developments; individual stocks warrant deep-dive research.

    "Like biotech... much safer to play the trend for 20% gains in three, four months versus trying to hit it out of the park..." — Lou [16:45]

5. Small Caps: Forgotten Alpha

[17:05–19:54]

• Valuation and Earnings Turnaround:
  • After years of lagging large caps, small caps’ unprofitable share declined from 44% to 28%; revenue and earning projections are now 2–3x higher than large caps for 2027–28.
• Active Management Edge:
  • Lou argues small cap investing favors diligent individuals (less analyst coverage, less institutional interest).

    "This is an area... the last bastion of opportunity for the individual investor..." — Lou [18:27]

• ETFs and Stock Picking:
  • Start with IWM (Russell 2000) or IWC (micro caps), then seek individual outliers from within those baskets.

6. Under-the-Radar Stock: Halozyme (HALO)

[20:17–21:18]

• Business Model:
  • Enables subcutaneous delivery of drugs, turning multi-hour infusions into five-minute injections; profits via royalties.
  • Lou likens it to ARM Holdings’ licensing structure, but for biotech.

    "They take a two hour infusion and turn it into like a five minute shot." — Lou [20:47]

7. Apple: Still a Long-Term Winner

[21:46–24:43]

• Misunderstood AI Narrative:
  • Apple is routinely criticized or praised for not chasing AI hype; Lou argues their strength lies in dominating consumer ecosystems, not developing frontier models.

    "Apple does not need to have a frontier AI model... Their bread and butter is the consumer... they've always outsourced their technology..." — Lou [22:30]

  • Apple’s incremental product iteration (not major innovation) continues to yield massive, compounding profits.
• Stock Perspective:
  • While Apple has underperformed (only up 11% YoY), Lou is a steady buyer for the long-term, calling it “lower risk” exposure to tech.

8. GLP-1 Drugs: Next Blockbuster Theme

[25:06–28:03]

• Eli Lilly vs. Novo Nordisk:
  • Lou is “absolutely levered” to this theme given GLP-1s’ broad impact (diabetes, obesity, metabolic, some autoimmune diseases).
  • Eli Lilly has the superior drug pipeline; Lou expects it to become the next multi-trillion market cap pharma giant.

    "Eli Lilly actually has a next generation peptide called retatrutide... stack them up... Eli Lilly's drugs are superior." — Lou [26:10]

  • Speculative pick: Viking Therapeutics (VKTX), possibly even more effective drugs, but earlier clinical stage.
• Demographic Tailwinds:
  • Massive market demand for both medical and cosmetic benefits will sustain sector growth.

Notable Quotes & Memorable Moments

• "AI should stand for accelerated innovation." — Lou [05:18]
• "Is anyone going to give up their Microsoft Office suite? I don't think so." — Lou [02:57]
• "This is an area… the last bastion of opportunity for the individual investor…” — Lou [18:27]
• "Apple... just needs to iterate to thrive." — Lou [23:18]
• "Eli Lilly... is the next multi trillion dollar market cap, big pharma." — Lou [26:05]

Timestamps of Key Segments

• [00:00–06:08]: AI’s misunderstood impact & market opportunities
• [06:08–08:30]: Big tech layoffs—AI scapegoat or needed right-sizing?
• [09:37–14:54]: Biotech’s M&A wave and how to play it (XBI, HALO)
• [14:54–17:05]: Energy’s contrarian run and how to get exposure
• [17:05–19:54]: Small caps rebound & strategic stock picking
• [20:17–21:18]: Deep dive on Halozyme (HALO), a biotech royalty model
• [21:46–24:43]: Apple’s misunderstood AI stance and long-term outlook
• [25:06–28:03]: GLP-1 drug market (Eli Lilly, VKTX) and demographic tailwinds

Final Thoughts

Lou Basenese packs this episode with sharp, actionable insight on high-potential names and sectors overlooked or misread by the mainstream narrative. His thesis: follow fundamentals, embrace market dislocations, and use ETFs for broad exposure before digging deeper into individual stock ideas. If you want to find alpha “where no one is looking,” this episode delivers a roadmap.

Where to Find Lou Basenese

• Newsletter: thebigskinny.com
• X (Twitter): @LouBasenese

For more from Phil Rosen, subscribe to Opening Bell Daily.